Vitrase Gains New Molecular Entity Status Due To Lack Of Characterization
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NME or not NME? FDA’s question is whether Vitrase is the same as previously approved hyaluronidase. Agency concludes activity shown by USP test supports approval for 505(b)(2) NDA; lack of characterization qualifies Ista’s ovine hyaluronidase for five years of exclusivity
You may also be interested in...
Baxter/Halozyme Hyaluronidase Enhanze SC Set For Approval By September
Halozyme human-derived hyaluronidase Enhanze SC user fee goal is September 23 following March 23 NDA submission for use as spreading agent. Firm is highlighting greater purity than animal-derived hyaluronidase products. Baxter to market product, provide fill/finish services
FDA Clears 31 New Molecular Entities In 2004, Up 10 From Previous Year
NME rebound in 2004? Final count is 31 versus 21 in 2003 – however, 2004 tally includes several atypical new molecular entities. Top 10 pharma companies hold small share of the total, with no companies clearing more than two NMEs during the year. Over 20% of the approvals came in the last two weeks of December
FDA Clears 31 New Molecular Entities In 2004, Up 10 From Previous Year
NME rebound in 2004? Final count is 31 versus 21 in 2003 – however, 2004 tally includes several atypical new molecular entities. Top 10 pharma companies hold small share of the total, with no companies clearing more than two NMEs during the year. Over 20% of the approvals came in the last two weeks of December